Fiche centre
Shanghai Chest hospital
Shanghai — China
Essais liés3clinical trials
VilleShanghailocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04858958
Essais cliniques associés
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Amivantamab | Cancer | Phase 3 | NCT04538664 | PAPILLON — A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | ACTIVE_NOT_RECRUITING |
| Adagrasib | Cancer | Phase 3 | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING |
| Furmonertinib 160mg | Cancer | Phase 1 | NCT04858958 | FAVOUR — Study of FURMONERTINIB in Patients With NSCLC Having Exon 20 Insertion Mutation | COMPLETED |